Status:

COMPLETED

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

Lead Sponsor:

Genzyme, a Sanofi Company

Conditions:

Fabry Disease

Eligibility:

MALE

16+ years

Phase:

PHASE2

Brief Summary

People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the alpha-galactosidase A enzyme. This enzyme helps to break down and remove certain types of ...

Eligibility Criteria

Inclusion

  • Have clinical manifestations of Fabry disease
  • All patients have to have a plasma αGAL activity of \< 1.5 nmol/hr/mL or a documented leukocyte αGAL activity of \< 4 nmol/hr/mg
  • Patient or patient's parent/guardian had to provide written informed consent prior to any study-related procedures being performed
  • Patients had to be male and ≥ 16 years of age

Exclusion

  • There is evidence of renal insufficiency, as defined by serum creatinine greater than or equal to 2.2 mg/dL (194.7 μmol/L) AND/OR has an estimated glomerular filtration rate (GFR) of \<80 mL/min (using the equation derived from the Modification of Diet in Renal Disease Study (MDRD))
  • Has undergone kidney transplantation or is currently on dialysis
  • Has a clinically significant organic disease or an unstable condition (with the exception of symptoms relating to Fabry disease) that in the opinion of the Investigator would preclude participation in the trial
  • Has participated in a study employing an investigational drug within 30 days of the start of this trial
  • Patients who received prior treatment with enzyme replacement therapy for Fabry disease
  • Patient was unable to comply with the requirements of the protocol

Key Trial Info

Start Date :

June 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2007

Estimated Enrollment :

21 Patients enrolled

Trial Details

Trial ID

NCT00196716

Start Date

June 1 2003

End Date

March 1 2007

Last Update

April 3 2015

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

II. interní klinika 1. LF UK

Prague, Czechia, 128 02

2

Tartu University Clinics, Department of Internal Medicine

Tartu, Estonia, 51014

3

Klinika Chorob Metabolicznych, Instytut "Pomnik-Centrum Zdrowia Dziecka"

Warsaw, Poland, 04-736

4

Detská fakultná nemocnica Kramáre I. Interná klinika

Bratislava, Slovakia, 833 40